AAAAAA

   
Results: 1-7 |
Results: 7

Authors: Greco, O Patterson, AV Dachs, GU
Citation: O. Greco et al., Can gene therapy overcome the problem of hypoxia in radiotherapy?, J RADIAT R, 41(3), 2000, pp. 201-212

Authors: Braybrooke, JP Propper, DJ O'Byrne, KJ Koukourakis, MI Patterson, AV Houlbrook, S Love, SD Varcoe, S Taylor, M Ganesan, TS Talbot, DC Harris, AL
Citation: Jp. Braybrooke et al., Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha, BR J CANC, 83(2), 2000, pp. 219-224

Authors: Saunders, MP Patterson, AV Chinje, EC Harris, AL Stratford, IJ
Citation: Mp. Saunders et al., NADPH : cytochrome C (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line, BR J CANC, 82(3), 2000, pp. 651-656

Authors: Saunders, MP Jaffar, M Patterson, AV Nolan, J Naylor, MA Phillips, RM Harris, AL Stratford, IJ
Citation: Mp. Saunders et al., The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions, BIOCH PHARM, 59(8), 2000, pp. 993-996

Authors: Chinje, EC Patterson, AV Saunders, MP Lockyer, SD Harris, AL Stratford, IJ
Citation: Ec. Chinje et al., Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?, BR J CANC, 81(7), 1999, pp. 1127-1133

Authors: Patterson, AV Saunders, MP Chinje, EC Patterson, LH Stratford, IJ
Citation: Av. Patterson et al., Enzymology of tirapazamine metabolism: a review, ANTI-CAN DR, 13(6), 1998, pp. 541-573

Authors: Patterson, AV Stratford, IJ
Citation: Av. Patterson et Ij. Stratford, Exploiting tumour-specific physiology to target redox-dependent molecular chemotherapy, EUROCANCER 98, 1998, pp. 285-287
Risultati: 1-7 |